Suppr超能文献

异基因造血细胞移植后的非传染性肺毒性。

Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation.

机构信息

Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin; Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

出版信息

Transplant Cell Ther. 2022 Jun;28(6):310-320. doi: 10.1016/j.jtct.2022.03.015. Epub 2022 Mar 18.

Abstract

Noninfectious pulmonary toxicity (NPT), a significant complication of allogeneic hematopoietic cell transplantation (alloHCT), includes idiopathic pneumonia syndrome (IPS), diffuse alveolar hemorrhage (DAH), and cryptogenic organizing pneumonia (COP), with an overall incidence ranging from 1% to 15% in different case series and a variable mortality rate. A registry study of the epidemiology and outcomes of NPT after alloHCT has not been conducted to date. The primary objective of the present study was to assess the incidence of and risk factors for IPS, DAH, and COP; the secondary objective was to assess overall survival (OS) in patients developing NPT. This retrospective study included adult patients who underwent alloHCT between 2008 and 2017 and reported to the Center for International Blood and Marrow Transplant Research. Multivariable Cox proportional hazards regression models were developed to identify the risk factors for development of NPT and for OS, by including pretransplantation clinical variables and time-dependent variables of neutrophil and platelet recovery, and acute graft-versus-host disease (GVHD) post-transplantation. This study included 21,574 adult patients, with a median age of 55 years. According to the HCT Comorbidity Index (HCT-CI), 24% of the patients had moderate pulmonary comorbidity and 15% had severe pulmonary comorbidity. The cumulative incidence of NPT at 1 year was 8.1% (95% confidence interval [CI], 7.7% to 8.5%). Individually, the 1-year cumulative incidences of IPS, DAH, and COP were 4.9% (95% CI, 4.7% to 5.2%), 2.1% (95% CI, 1.9% to 2.3%), and .7% (95% CI, .6% to .8%), respectively. Multivariable analysis showed that severe pulmonary comorbidity, grade II-IV acute GVHD, mismatched unrelated donor and cord blood transplantation, and HCT-CI score ≥1 significantly increased the risk of NPT. In contrast, alloHCT performed in 2014 or later, non-total body irradiation (TBI)- and TBI-based nonmyeloablative conditioning and platelet recovery were associated with a decreased risk. In a landmark analysis at day+100 post-transplantation, the risk of DAH was significantly lower in patients who had platelet recovery by day +100. Multivariable analysis for OS demonstrated that NPT significantly increased the mortality risk (hazard ratio, 4.2; P < .0001).

摘要

非传染性肺毒性(NPT)是异基因造血细胞移植(alloHCT)的一种严重并发症,包括特发性肺炎综合征(IPS)、弥漫性肺泡出血(DAH)和隐源性机化性肺炎(COP),不同病例系列中的总发生率为 1%至 15%,死亡率各不相同。迄今为止,尚未对 alloHCT 后 NPT 的流行病学和结局进行登记研究。本研究的主要目的是评估 IPS、DAH 和 COP 的发生率和危险因素;次要目的是评估发生 NPT 的患者的总生存率(OS)。这项回顾性研究纳入了 2008 年至 2017 年间在国际血液和骨髓移植研究中心接受 alloHCT 并报告的成年患者。通过包括移植前临床变量和中性粒细胞及血小板恢复的时间依赖性变量,以及移植后急性移植物抗宿主病(GVHD),建立多变量 Cox 比例风险回归模型,以确定发生 NPT 和 OS 的危险因素。该研究共纳入 21574 例成年患者,中位年龄为 55 岁。根据 HCT 合并症指数(HCT-CI),24%的患者有中度肺部合并症,15%的患者有严重肺部合并症。NPT 在 1 年内的累积发生率为 8.1%(95%置信区间[CI],7.7%至 8.5%)。单独来看,IPS、DAH 和 COP 在 1 年内的累积发生率分别为 4.9%(95%CI,4.7%至 5.2%)、2.1%(95%CI,1.9%至 2.3%)和 0.7%(95%CI,0.6%至 0.8%)。多变量分析表明,严重肺部合并症、Ⅱ至Ⅳ级急性 GVHD、不匹配无关供者和脐带血移植以及 HCT-CI 评分≥1 显著增加了 NPT 的风险。相反,在 2014 年或以后进行的 alloHCT、非全身体照射(TBI)和 TBI 为基础的非清髓性预处理以及血小板恢复与风险降低相关。在移植后第 100 天的时间标志分析中,血小板恢复至第 100 天的患者 DAH 风险显著降低。OS 的多变量分析表明,NPT 显著增加了死亡率风险(风险比,4.2;P<.0001)。

相似文献

1
Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation.
Transplant Cell Ther. 2022 Jun;28(6):310-320. doi: 10.1016/j.jtct.2022.03.015. Epub 2022 Mar 18.
2
Epidemiology of Diffuse Alveolar Hemorrhage in Pediatric Allogeneic Hematopoietic Cell Transplantation Recipients.
Transplant Cell Ther. 2024 Oct;30(10):1017.e1-1017.e12. doi: 10.1016/j.jtct.2024.07.022. Epub 2024 Jul 31.
6
Incidence, Risk Factors, and Outcomes of Idiopathic Pneumonia Syndrome after Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2020 Feb;26(2):413-420. doi: 10.1016/j.bbmt.2019.09.034. Epub 2019 Oct 9.
9
Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant. 2017 Dec;23(12):2096-2101. doi: 10.1016/j.bbmt.2017.08.007. Epub 2017 Aug 15.
10
Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation.
Biol Blood Marrow Transplant. 2001;7(4):223-9. doi: 10.1053/bbmt.2001.v7.pm11349809.

引用本文的文献

1
Fatal SARS-CoV-2 Reactivation After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia.
Cureus. 2025 Jul 1;17(7):e87084. doi: 10.7759/cureus.87084. eCollection 2025 Jul.
3
Organ-specific microenvironments drive divergent T cell evolution in acute graft-versus-host disease.
Sci Transl Med. 2025 Jan 29;17(783):eads1298. doi: 10.1126/scitranslmed.ads1298.
4
Pulmonary complications of bone marrow transplantation.
Breathe (Sheff). 2024 Oct 1;20(3):240043. doi: 10.1183/20734735.0043-2024. eCollection 2024 Oct.
5
Pulmonary Function after Nonmyeloablative Hematopoietic Cell Transplant for Sickle Cell Disease.
Ann Am Thorac Soc. 2024 Oct;21(10):1398-1406. doi: 10.1513/AnnalsATS.202309-771OC.
6
Acute GVHD classification based on the dynamics of GVHD skin involvement from its appearance to the start of systemic treatment.
Bone Marrow Transplant. 2024 Jan;59(1):17-22. doi: 10.1038/s41409-023-02107-z. Epub 2023 Sep 25.
8
Impact of lung function impairment after allogeneic hematopoietic stem cell transplantation.
Sci Rep. 2022 Aug 19;12(1):14155. doi: 10.1038/s41598-022-18553-6.

本文引用的文献

1
Diffuse Alveolar Hemorrhage After Pediatric Hematopoietic Stem Cell Transplantation.
Front Oncol. 2020 Sep 9;10:1757. doi: 10.3389/fonc.2020.01757. eCollection 2020.
2
Noninfectious pulmonary complications of haematopoietic stem cell transplantation.
Eur Respir Rev. 2020 Jun 23;29(156). doi: 10.1183/16000617.0119-2019. Print 2020 Jun 30.
3
Findings on cryptogenic organizing pneumonia: a case report and literature review.
J Int Med Res. 2020 Apr;48(4):300060520920068. doi: 10.1177/0300060520920068.
4
Incidence, Risk Factors, and Outcomes of Idiopathic Pneumonia Syndrome after Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2020 Feb;26(2):413-420. doi: 10.1016/j.bbmt.2019.09.034. Epub 2019 Oct 9.
5
Transfusion-associated circulatory overload and transfusion-related acute lung injury.
Blood. 2019 Apr 25;133(17):1840-1853. doi: 10.1182/blood-2018-10-860809. Epub 2019 Feb 26.
6
Respiratory failure in the hematopoietic stem cell transplant recipient.
World J Crit Care Med. 2018 Oct 16;7(5):62-72. doi: 10.5492/wjccm.v7.i5.62.
7
Diffuse alveolar hemorrhage is most often fatal and is affected by graft source, conditioning regimen toxicity, and engraftment kinetics.
Haematologica. 2018 Dec;103(12):2109-2115. doi: 10.3324/haematol.2018.189134. Epub 2018 Aug 3.
8
Diagnostic and Prognostic Plasma Biomarkers for Idiopathic Pneumonia Syndrome after Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2018 Apr;24(4):678-686. doi: 10.1016/j.bbmt.2017.11.039. Epub 2017 Dec 6.
9
Bronchiolitis Obliterans Syndrome and Other Late Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.
Clin Chest Med. 2017 Dec;38(4):607-621. doi: 10.1016/j.ccm.2017.07.003. Epub 2017 Sep 19.
10
Engraftment Syndrome after Autologous Stem Cell Transplantation: An Update Unifying the Definition and Management Approach.
Biol Blood Marrow Transplant. 2015 Dec;21(12):2061-2068. doi: 10.1016/j.bbmt.2015.08.030. Epub 2015 Aug 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验